Dashboard
Manage Tickers

RARE


   

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

ionis-pharmaceuticals-to-expedite-development-of-rare-neurological-disease-candidate-with-fda-breakthrough-status
Ionis Pharmaceuticals To Expedite Developm...
09/09/2025 17:51:26

FDA designates Ionis Breakthrough Therapy for Angelman syndrome after Phase 1/2 results showed functional improvements.

hc-wainwright--co-reiterates-buy-on-ultragenyx-pharmaceutical-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Ultr...
09/09/2025 10:16:42

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintai...

ultragenyx-reports-96-week-phase-3-results-for-dtx401-in-gsdia-showing-greater-reductions-in-cornstarch-use-and-sustained-glycemic-control
Ultragenyx Reports 96-Week Phase 3 Results...
09/08/2025 20:18:59

At Week 96 participants experienced even greater reductions in daily cornstarch intake while maintaining low levels of hypoglyc...

assessing-ultragenyx-pharmaceutical-insights-from-8-financial-analysts
Assessing Ultragenyx Pharmaceutical: Insig...
09/05/2025 14:01:03

cantor-fitzgerald-reiterates-overweight-on-ultragenyx-pharmaceutical-maintains-105-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/05/2025 13:44:07

Cantor Fitzgerald analyst Kristen Kluska reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and maintains ...

fda-outlines-process-to-speed-up-rare-disease-therapy-approvals
FDA Outlines Process To Speed Up Rare Dise...
09/04/2025 18:50:03

FDA launches Rare Disease Evidence Principles to guide therapy reviews, offering new pathways for approval while raising questi...

Core News & Articles
10 Health Care Stocks Whale Activity In To...
09/02/2025 17:35:29

ultragenyx-initiates-rolling-submission-of-a-biologics-license-application-to-the-fda-for-its-dtx401-aav-gene-therapy-in-glycogen-storage-disease-type-ia
Ultragenyx Initiates Rolling Submission Of...
08/18/2025 12:04:53

canaccord-genuity-maintains-buy-on-ultragenyx-pharmaceutical-lowers-price-target-to-128
Canaccord Genuity Maintains Buy on Ultrage...
08/08/2025 21:36:37

Canaccord Genuity analyst Whitney Ijem maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and lowers the price tar...

8-analysts-assess-ultragenyx-pharmaceutical-what-you-need-to-know
8 Analysts Assess Ultragenyx Pharmaceutica...
08/06/2025 22:01:05

cantor-fitzgerald-maintains-overweight-on-ultragenyx-pharmaceutical-lowers-price-target-to-105
Cantor Fitzgerald Maintains Overweight on ...
08/06/2025 14:17:39

Cantor Fitzgerald analyst Kristen Kluska maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the ...

ultragenyx-pharmaceutical-affirms-fy2025-sales-guidance-of-64000m-67000m-vs-65327m-est
Ultragenyx Pharmaceutical Affirms FY2025 S...
08/05/2025 20:02:45

Ultragenyx Pharmaceutical (NASDAQ:RARE) affirms FY2025 sales outlook from $640.00 million-$670.00 million to $640.00 million-$6...

ultragenyx-pharmaceutical-q2-eps-117-beats-132-estimate-sales-16650m-beat-16250m-estimate
Ultragenyx Pharmaceutical Q2 EPS $(1.17) B...
08/05/2025 20:01:57

Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.17) per share which beat the analyst consensus estimat...

Core News & Articles
Earnings Scheduled For August 5, 2025
08/05/2025 08:32:54

Core News & Articles
12 Health Care Stocks Moving In Monday's A...
08/04/2025 21:07:07

what-to-expect-from-ultragenyx-pharmaceuticals-earnings
What to Expect from Ultragenyx Pharmaceuti...
08/04/2025 17:04:13

ultragenyx-completes-enrollment-in-its-phase-3-aspire-study-of-apazunersen-for-angelman-syndrome
Ultragenyx Completes Enrollment In Its Pha...
07/31/2025 20:42:33

ultragenyx-represents-intriguing-buying-opportunity-despite-recent-setbacks
Ultragenyx Represents 'Intriguing Buying O...
07/28/2025 17:16:04

HC Wainwright initiates Ultragenyx at Buy with $80 target, citing strong rare disease pipeline and late-stage data expected by ...

beyond-the-numbers-7-analysts-discuss-ultragenyx-pharmaceutical-stock
Beyond The Numbers: 7 Analysts Discuss Ult...
07/28/2025 12:00:51

hc-wainwright--co-assumes-ultragenyx-pharmaceutical-at-buy-announces-price-target-of-80
HC Wainwright & Co. Assumes Ultragenyx Pha...
07/28/2025 10:30:02

HC Wainwright & Co. analyst Raghuram Selvaraju assumes Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy rating and ann...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION